Publication date: Aug 08, 2019
This study will compare medically-supervised withdrawal (MSW, ‘detoxification’) to opioid agonist treatment (OAT, ‘maintenance’) with buprenorphine for pregnant women with opioid use disorder in terms of maternal, fetal, and neonatal outcomes. Outcomes will be assessed during pregnancy, at birth and for 12 months postpartum. This study has the potential to impact health service policy and practices in terms of the treatment options of pregnant women with opioid use disorder.
- National Partnership for Maternal Safety: Consensus Bundle on Obstetric Care for Women With Opioid Use Disorder.
- Perinatal Opioid Use
- Ketamine to Improve Recovery After Cesarean Delivery – Part 1
- The Cost of the Opioid Epidemic, In Context
- The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis